ArticleScientific reports2025
A novel angiogenesis-related gene signature predicting prognosis in clear cell renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cancer and is characterized by high recurrence and metastasis rates. A key feature of ccRCC is its rich vascular network, which supports tumor growth and metastasis through angiogenesis, the process of forming new blood vessels. Anti-angiogenic therapy targeting the vascular endothelial growth factor (VEGF) pathway has shown efficacy in treating advanced ccRCC, but resistance often develops, highlighting the need for new therapeutic targets. We systematically screened differentially expressed genes (DEGs) between ccRCC and normal tissues using TCGA-KIRC data, and intersected them with angiogenesis-related genes from GeneCards and MSigDB. Survival analysis identified prognostic genes, and a multigene risk signature was established and validated using an independent GEO cohort (GSE29609). Functional analyses and immunohistochemistry were performed to explore the biological roles of the key gene RUNX1. A total of 27 ccRCC-related angiogenesis genes were identified, of which four formed a prognostic signature with strong predictive value. Among them, RUNX1 carried the greatest prognostic weight. Functional validation revealed that RUNX1 promotes ccRCC progression by regulating immune infiltration and lipid metabolism. In particular, RUNX1 expression was associated with enhanced CD8⁺ T-cell infiltration and upregulation of lipid metabolism genes such as FASN and SCD1. Our study identifies a novel angiogenesis-related prognostic signature for ccRCC and highlights RUNX1 as a key regulator linking tumor angiogenesis, immune infiltration, and lipid metabolism. Compared with conventional anti-VEGF therapies, targeting RUNX1 may provide broader therapeutic benefits and represents a promising translational strategy for improving ccRCC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.